Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to ce...

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

Phase 3

Completed

Conditions: Childhood Mixed Cellularity Classical Hodgkin Lymphoma
Stage I Childhood Hodgkin Lymphoma
Stage IV Childhood Hodgkin Lymphoma
Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma
Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma
Stage II Childhood Hodgkin Lymphoma
Childhood Nodular Sclerosis Classical Hodgkin Lymphoma
Stage III Childhood Hodgkin Lymphoma

Interventions: Biological: Bleomycin Sulfate
Drug: Cyclophosphamide
Drug: Cisplatin
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Cytarabine
Biological: Filgrastim
Drug: Dexamethasone
Radiation: Involved-Field Radiation Therapy
Drug: Prednisone
Drug: Vincristine Sulfate Liposome

First Posted Date: 2003-01-27

Last Posted Date: 2017-04-12

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 1734

Registration Number: NCT00025259

Locations: 🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 172 locations

Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors

Phase 3

Completed

Conditions: Kidney Cancer

Interventions: Biological: dactinomycin
Biological: filgrastim
Drug: cyclophosphamide
Drug: carboplatin
Drug: doxorubicin hydrochloride
Procedure: conventional surgery
Drug: etoposide
Drug: vincristine sulfate
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2014-07-25

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 203

Registration Number: NCT00002610

Locations: 🇺🇸
Children's Hospital Central California, Madera, California, United States
🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
Floating Hospital for Children, Boston, Massachusetts, United States

and more 231 locations

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 3

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2003-01-27

Last Posted Date: 2010-06-22

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Registration Number: NCT00002517

Locations: 🇫🇷
Centre Hospitalier Regional et Universitaire d'Angers, Angers, France
🇧🇪
Algemeen Ziekenhuis Middelheim, Antwerp, Belgium
🇧🇪
Hopital Universitaire Des Enfants Reine Fabiola, Brussels, Belgium

and more 20 locations

Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2010-06-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 36

Registration Number: NCT00006260

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2010-06-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 54

Registration Number: NCT00049439

Locations: 🇺🇬
Uganda Cancer Institute, Kampala, Uganda
🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States
🇰🇪
University of Nairobi College of Health Sciences, Nairobi, Kenya

and more 1 locations

Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Drug: carmustine
Drug: cisplatin
Drug: etoposide
Drug: cyclophosphamide
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2010-06-10

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 37

Registration Number: NCT00028665

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio, United States

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Phase 3

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2003-01-27

Last Posted Date: 2010-05-27

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 80

Registration Number: NCT00002926

Locations: 🇧🇪
Hopital Universitaire Erasme, Brussels, Belgium
🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇨🇿
Institute of Hematology and Blood Transfusion, Prague, Czech Republic

and more 37 locations